PRKG1 and neoplasm: In the present study, the expression of most stimulatory and inhibitory immunomodulators was significantly lower in the low-PRKG1-expressed group, which might be attributed to the downregulation of pre-existing immune cells infiltrating, further indicating the regulatory role of PRKG1 in tumor immunotherapy.